Combination therapy for severe alcoholic hepatitis
Treatments studied
Part of Digestive system, Mental health clinical trials.
This trial tests a combination of treatments for people with severe alcohol-related liver disease (alcoholic hepatitis) that has not responded to standard care. The goal is to improve liver function and help you stop drinking.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 69 years old.
- You have severe alcoholic hepatitis, which means you have jaundice (yellowing of skin/eyes) and abnormal liver tests, and you have had heavy alcohol use.
- Your MELD score (a measure of liver disease severity) is between 20 and 35.
- You can stop drinking alcohol and are willing to undergo treatment for alcohol use.
- You do not have an active infection, kidney failure, or other serious medical conditions that would make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving a protein called alpha-1 antitrypsin can help people with severe liver inflammation caused by heavy drinking. It may reduce the damage and improve recovery.
This early-phase study is testing a treatment approach for people with alcoholic hepatitis (liver inflammation caused by heavy alcohol use). It may help by improving liver function and outcomes in people who meet specific lab and health criteria.
This trial tests whether giving corticosteroids for a longer time, or adding a medicine called N-acetylcysteine, can help people with severe alcoholic hepatitis. It is for patients who have been drinking heavily and recently developed jaundice.
This trial tests a new medicine called larsucosterol to see if it helps people with severe alcohol-related hepatitis (liver inflammation from heavy drinking). If you qualify, the study will monitor your safety and recovery over 90 days.
This trial tests a new medicine called MRG-001 for people with severe alcoholic hepatitis, a liver condition caused by heavy drinking. The study aims to see if the drug can help improve liver function and reduce symptoms.
This trial studies whether people with alcohol-related hepatitis can see their liver function improve. It looks at patients whose diagnosis is supported by blood tests and imaging, and excludes those with liver cancer.
Hear when a new Alcohol-Associated Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.